Altimmune, Inc., a biopharmaceutical company, is facing a class action lawsuit following a significant setback in its IMPACT Phase 2b MASH trial. The lawsuit, filed on behalf of shareholders, alleges securities fraud that has led to substantial financial losses for investors between August 10, 2023, and June 25, 2025. The controversy erupted after Altimmune released a press statement on June 26, 2025, revealing that the trial of their drug Pemvidutide failed to achieve statistical significance in reducing fibrosis, a key endpoint. This unexpected outcome was attributed to a higher-than-anticipated placebo response, leaving investors and analysts questioning the company’s prior optimistic projections.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The market reacted swiftly to the news, causing Altimmune’s stock to plummet by 53.2% overnight, from $7.71 to $3.61 per share. This dramatic decline underscores the gravity of the situation for shareholders who had placed their trust in the company’s promising forecasts.
For those who have incurred losses during this period, there is an opportunity to seek recovery. Affected investors are encouraged to visit [this link](https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?wire=18) to understand their rights and explore the possibility of joining the class action. Participation comes with no cost or obligation.
Levi & Korsinsky LLP is dedicated to representing all plaintiffs seeking justice in this case. With over two decades of experience and a track record of securing substantial settlements for shareholders, Levi & Korsinsky stands as a formidable advocate for investors seeking justice.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171